Direct-to-implant or two-stage breast reconstruction in pathogenic mutations carriers after risk-reducing nipple-sparing mastectomy: A real-world multicenter cohort
Gene / mechanism
Germline pathogenic variants predisposing to breast cancer
Summary
In carriers of a germline pathogenic variant undergoing risk-reducing nipple-sparing mastectomy, the choice between immediate direct-to-implant (DTI) and two-stage tissue expander (TE) reconstruction remains debated. This retrospective multicentre cohort included 523 patients (742 breasts) operated on between 2008 and 2025, 447 (85.5%) with DTI and 76 (14.5%) with TE reconstruction, using propensity score-based inverse probability of treatment weighting (IPTW) as the primary analysis. Early complications did not differ (19.0% vs 21.1%), but TE was associated with more Baker grade III capsular contracture (18.4% vs 7.0%) and worse aesthetic outcomes. In the weighted analysis, TE remained associated with increased capsular contracture (weighted OR 3.69; absolute risk difference +15.1%) and a lower likelihood of favourable aesthetic outcome (weighted OR 0.32). The authors conclude that DTI is safe and effective in appropriately selected patients, with non-blinded aesthetic assessment calling for caution.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
The question is very practical for carriers considering prophylactic mastectomy, and the sample size is substantial for such a targeted population. The group imbalance (only 76 expanders), retrospective data collection over nearly two decades and non-blinded aesthetic assessment nonetheless limit the reach of the conclusion. These data inform preoperative counselling without settling the choice for every profile.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 6/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime